BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 12823724)

  • 1. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
    Hyland C; Seed CR; Kiely P; Parker S; Cowley N; Bolton W
    Vox Sang; 2003 Jul; 85(1):1-8. PubMed ID: 12823724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening.
    Dow BC; Munro H; Buchanan I; Ferguson K; Davidson F; Lycett C; Jarvis M; Cleland A; Petrik J; Lumley S; MacLean A
    Vox Sang; 2004 Jan; 86(1):15-20. PubMed ID: 14984555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
    Kleinman SH; Stramer SL; Brodsky JP; Caglioti S; Busch MP
    Transfusion; 2006 May; 46(5):695-702. PubMed ID: 16686836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays.
    Galel SA; Strong DM; Tegtmeier GE; Holland PV; Kuramoto IK; Kemper M; Pietrelli L; Gallarda J
    Transfusion; 2002 Nov; 42(11):1507-13. PubMed ID: 12421226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe.
    Roth WK; Weber M; Buhr S; Drosten C; Weichert W; Sireis W; Hedges D; Seifried E
    Transfusion; 2002 Jul; 42(7):862-8. PubMed ID: 12375658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing.
    Shan H; Ren FR; Zhao HY; Zhang YZ; Wen GX; Yao FZ; Gao GJ; Yan LX; Jiang CF; Bai XH; Tiemuer MH; Tu YQ; Zhu FM; Zheng YR; Cui L; Liu CL; Gong XY; Lv QS; Zheng P; Ziermann R; Ness P; Wang JX
    Transfusion; 2007 Nov; 47(11):2011-6. PubMed ID: 17958529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV.
    Hitzler WE; Runkel S
    Transfusion; 2001 Mar; 41(3):333-7. PubMed ID: 11274586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of HCV screening of volunteer blood donors with a chemiluminescent immunoassay and a second- or third-generation EIA: overlap of false-positive reactivity and its impact on donor management.
    Kiely P; Wilson D
    Transfusion; 2000 May; 40(5):580-4. PubMed ID: 10827263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
    Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
    Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide nucleic acid amplification testing of hepatitis B virus, hepatitis C virus and human immunodeficiency virus type 1 for blood transfusion and follow-up study of nucleic acid amplification positive donors.
    Japanese Red Cross NAT Screening Research Group
    Jpn J Infect Dis; 2000 Jun; 53(3):116-23. PubMed ID: 10957709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.
    Makroo RN; Choudhury N; Jagannathan L; Parihar-Malhotra M; Raina V; Chaudhary RK; Marwaha N; Bhatia NK; Ganguly AK
    Indian J Med Res; 2008 Feb; 127(2):140-7. PubMed ID: 18403791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.
    Mison L; Seed CR; Margaritis AR; Hyland C;
    Vox Sang; 2003 Jan; 84(1):11-9. PubMed ID: 12542729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of hepatitis C virus in Brazilian blood donors using a reverse transcriptase nested polymerase chain reaction: comparison with enzyme immunoassay and recombinant protein immunoblot assay.
    Gonçales NS; Costa FF; Vassallo J; Gonçales FL
    Rev Inst Med Trop Sao Paulo; 2000; 42(5):263-7. PubMed ID: 11058936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of an algorithm for anti HCV EIA reactivity in blood donor screening in Turkey in the absence of nucleic acid amplification screening.
    Karakoc AE; Berkem R; Irmak H; Demiroz AP; Yenicesu I; Ertugrul N; Arslan Ö; Kemahli S; Yilmaz S; Ozcebe O; Kara A; Ozet G; Acikgoz ZC; Acikgoz T
    Transfus Apher Sci; 2017 Oct; 56(5):732-737. PubMed ID: 28941882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays.
    Widell A; Månsson AS; Sundström G; Hansson BG; Nordenfelt E
    J Med Virol; 1991 Dec; 35(4):253-8. PubMed ID: 1724983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.
    Assal A; Barlet V; Deschaseaux M; Dupont I; Gallian P; Guitton C; Morel P; van Drimmelen H; David B; Lelie N; De Micco P
    Transfusion; 2009 Feb; 49(2):301-10. PubMed ID: 19389212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.